EcnoglutidevsMazdutide

Ecnoglutide is a long-acting GLP-1 receptor agonist engineered for once-weekly subcutaneous dosing using a structural design distinct from albumin-binding (semaglutide) or PEGylation. The molecule incorporates extended-half-life modifications that resist DPP-4 enzymatic degradation while maintaining high-affinity binding and full agonist activity at the GLP-1 receptor.

Receptor activation produces the standard GLP-1 pharmacology: glucose-dependent insulin secretion from pancreatic beta cells, suppression of glucagon release from alpha cells, slowed gastric emptying via vagal signalling, and central appetite suppression through hypothalamic and brainstem GLP-1 receptors. The clinical profile in Chinese Phase 3 trials closely mirrors semaglutide — approximately 14-15% body weight loss in obesity studies and substantial HbA1c reductions in type 2 diabetes trials — positioning ecnoglutide as a regional alternative to Wegovy and Ozempic with potentially lower pricing.

Ecnoglutide reflects a broader trend of Chinese biotech companies developing GLP-1 receptor agonists for both domestic and international markets. Sciwind Biosciences has filed for regulatory approval in China and is pursuing international development pathways. The molecule is one of several Chinese-developed GLP-1s approaching commercial launch alongside mazdutide, retatrutide-class triple agonists in early Chinese development, and a wave of biosimilar semaglutide products expected as patents expire in major markets through the late 2020s.

Mazdutide is a dual-receptor agonist that activates both GLP-1 and glucagon receptors, combining appetite suppression with increased energy expenditure. The GLP-1 component functions similarly to other GLP-1 agonists — binding to receptors in the hypothalamus to reduce hunger, stimulating glucose-dependent insulin secretion from pancreatic beta cells, and slowing gastric motility to prolong post-meal satiety.

The glucagon receptor component distinguishes mazdutide from pure GLP-1 agonists. Glucagon binding in the liver activates adenylyl cyclase, increasing cAMP and activating protein kinase A, which phosphorylates key enzymes in fatty acid oxidation and ketogenesis. This drives the liver to burn stored fat as fuel rather than accumulate it — a mechanism with direct therapeutic relevance for patients with metabolic-associated fatty liver disease (MAFLD). In adipose tissue, glucagon signaling promotes lipolysis and may activate thermogenic programs in brown and beige fat cells.

The engineering challenge in dual GLP-1/glucagon agonists is balancing the hyperglycemic effect of glucagon against the glucose-lowering effects of GLP-1. Mazdutide achieves this by tuning the relative receptor affinities so that GLP-1-mediated insulin secretion offsets glucagon-driven glucose production, resulting in net glycemic improvement alongside enhanced fat oxidation and energy expenditure.